Compare DexCom, Inc. (DXCM) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs ProShares UltraPro S&P500 — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: DexCom, Inc. is far larger — about 5.7× ProShares UltraPro S&P500's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and ProShares UltraPro S&P500 for 29 Days on average.
| DXCM | UPRO | |
|---|---|---|
Market Cap | $31.86B | $5.55B |
Volume | 3,607,070 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.34 | $157.66 |
52-Week Low | $54.84 | $89.29 |
Typical Hold Time | 62 Days | 29 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
UPRO trades at $153.19, down 1.3% on the day, with technical indicators showing a bullish moving average trend but neutral oscillators. The stock faces resistance at $155 and support at $151. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment around the broader market environment.
The outlook for UPRO is influenced by broader market dynamics, with Wall Street expecting continued S&P 500 gains but facing headwinds from concentration risks and economic uncertainty. Key opportunities include potential year-end rallies, while risks involve market volatility and earnings growth slowdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
